HOPX homeobox methylation in differentiated thyroid cancer and its clinical relevance.

ABSTRACT:

Background

The inactivation of the tumor-suppressor homeodomain-only protein X (HOPX) usually involves promoter methylation in several cancer types. This study aimed to investigate the HOPX-β mRNA expression and promoter methylation and their clinical relevance in differentiated thyroid cancer (DTC).

Patients and methods

Clinicopathological data and paraffin-embedded thyroid tumor tissues from 21 patients with DTC and 6 with benign tumors (T) and their non-tumor parenchyma (NT) were investigated. Tumor cell lines (FTC238, FTC236 and WRO) were treated with demethylating agent. HOPX-β mRNA expression was assessed by qRT-PCR and methylation status by Q-MSP. Thyroid cancer data from Cancer Genome Atlas (TCGA) was also collected.

Results

HOPX-β mRNA re-expression in two ce

SUBMITTER: Lima EU 

PROVIDER: S-EPMC6280589 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature